JP2008501716A5 - - Google Patents

Download PDF

Info

Publication number
JP2008501716A5
JP2008501716A5 JP2007515646A JP2007515646A JP2008501716A5 JP 2008501716 A5 JP2008501716 A5 JP 2008501716A5 JP 2007515646 A JP2007515646 A JP 2007515646A JP 2007515646 A JP2007515646 A JP 2007515646A JP 2008501716 A5 JP2008501716 A5 JP 2008501716A5
Authority
JP
Japan
Prior art keywords
medicament
syndrome
disease
autoinflammatory
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007515646A
Other languages
English (en)
Japanese (ja)
Other versions
JP5022216B2 (ja
JP2008501716A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/019674 external-priority patent/WO2005117945A1/en
Publication of JP2008501716A publication Critical patent/JP2008501716A/ja
Publication of JP2008501716A5 publication Critical patent/JP2008501716A5/ja
Application granted granted Critical
Publication of JP5022216B2 publication Critical patent/JP5022216B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007515646A 2004-06-04 2005-06-03 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法 Expired - Fee Related JP5022216B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57702304P 2004-06-04 2004-06-04
US60/577,023 2004-06-04
PCT/US2005/019674 WO2005117945A1 (en) 2004-06-04 2005-06-03 Methods of using il-1 antagonists to treat autoinflammatory disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012012800A Division JP2012111768A (ja) 2004-06-04 2012-01-25 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法

Publications (3)

Publication Number Publication Date
JP2008501716A JP2008501716A (ja) 2008-01-24
JP2008501716A5 true JP2008501716A5 (enExample) 2008-04-24
JP5022216B2 JP5022216B2 (ja) 2012-09-12

Family

ID=34972252

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007515646A Expired - Fee Related JP5022216B2 (ja) 2004-06-04 2005-06-03 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法
JP2012012800A Pending JP2012111768A (ja) 2004-06-04 2012-01-25 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012012800A Pending JP2012111768A (ja) 2004-06-04 2012-01-25 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法

Country Status (9)

Country Link
US (4) US7459426B2 (enExample)
EP (1) EP1750746A1 (enExample)
JP (2) JP5022216B2 (enExample)
CN (1) CN1964737B (enExample)
AU (1) AU2005249570B2 (enExample)
CA (1) CA2568352C (enExample)
IL (1) IL179512A0 (enExample)
MX (2) MXPA06014126A (enExample)
WO (1) WO2005117945A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005249503B2 (en) * 2003-11-10 2011-08-25 Vertex Pharmaceuticals Incorporated ICE inhibitors for the treatment of autoinflammatory diseases
AU2005216298B2 (en) 2004-02-26 2010-09-02 Baylor Research Institute Compositions and methods for the systemic treatment of arthritis
US20060160737A1 (en) * 2005-01-14 2006-07-20 Allen Radin Methods of using IL-1 antagonists to treat polymyalgia rheumatica and giant cell arteritis
EP2848258B1 (en) * 2005-10-26 2017-12-13 Novartis AG Treatment of familial Mediterranean Fever with anti IL-1beta antibodies
CN101378764A (zh) * 2005-12-09 2009-03-04 贝勒研究院 通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测
MX2009004051A (es) * 2006-10-20 2009-05-11 Regeneron Pharma Uso de antagonistas de il-1 para tratar gota y pseudo gota.
US7632490B2 (en) 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
JP5272735B2 (ja) * 2007-01-30 2013-08-28 国立大学法人 新潟大学 生物学的製剤
WO2008112772A2 (en) * 2007-03-14 2008-09-18 Baylor Research Institute Gene expression in peripheral blood mononuclear cells from children with diabetes
EP3406263A1 (en) * 2007-05-29 2018-11-28 Novartis AG New indications for anti-il-1beta therapy
KR20120082906A (ko) 2009-09-30 2012-07-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 자가포식현상-향상 유전자 생성물의 조절을 통한 자가포식현상의 조절 방법
ES2703774T3 (es) 2010-06-18 2019-03-12 Xbiotech Inc Tratamiento para la artritis
SG187231A1 (en) 2010-07-29 2013-02-28 Eleven Biotherapeutics Inc Chimeric il-1 receptor type i agonists and antagonists
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
JP6431476B2 (ja) * 2012-03-31 2018-11-28 アール−ファーム・インターナショナル・リミテッド・ライアビリティ・カンパニーＲ−Ｐｈａｒｍ Ｉｎｔｅｒｎａｔｉｏｎａｌ， Ｌｌｃ オステオプロテゲリン由来の組成物およびその使用
CN103509100B (zh) * 2012-06-15 2017-10-27 上海百迈博制药有限公司 一种白细胞介素‑1受体拮抗剂突变体
WO2014035361A1 (en) * 2012-08-26 2014-03-06 R-PHARM, CJSC (Closed Joint Stock Company) IL-1β INHIBITOR COMPOSITION AND USE THEREOF
CN107693781B (zh) 2013-03-13 2021-11-09 巴扎德制药公司 用于眼部递送的嵌合细胞因子制剂
AU2014274044B2 (en) * 2013-05-31 2019-06-27 Regeneron Pharmaceuticals, Inc. Methods of using IL-1 antagonists to treat Alzheimer's Disease
AU2014308751B2 (en) * 2013-08-22 2020-03-05 Acceleron Pharma, Inc. TGF-beta receptor type II variants and uses thereof
WO2015147789A1 (en) * 2014-03-24 2015-10-01 R-Pharm Overseas, Inc. Human il 1-r1 derived inhibitor of il-1b
JP6565099B2 (ja) * 2015-09-18 2019-08-28 国立大学法人 長崎大学 家族性地中海熱のバイオマーカー
BR112018006578A2 (pt) * 2015-10-01 2018-12-26 Heat Biologics, Inc. composições e métodos para juntar domínios extracelulares tipo i e tipo ii como proteínas quiméricas heterólogas
WO2017152254A1 (en) * 2016-03-09 2017-09-14 Chu Sainte-Justine Methods for reducing perinatal morbidity and/or mortality
EP3582813A4 (en) * 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS
AU2018249816B2 (en) * 2017-04-03 2025-04-17 Wisconsin Alumni Research Foundation Mineral coated microparticles for sustained delivery of biologically active molecules
EP3908613A4 (en) * 2019-01-07 2022-10-19 Celluris Participações Ltda. BISPECIFIC IN-TANDEM RECEPTOR CAR AND METHODS FOR MODULATION OF THE TUMOR MICROAREA
EP4054564A1 (en) * 2019-11-07 2022-09-14 Inflazome Limited Treatment of autoinflammatory disorders
JP7072260B2 (ja) * 2019-12-27 2022-05-20 国立大学法人愛媛大学 マックル・ウェルズ症候群の治療用医薬組成物
WO2021184128A1 (en) * 2020-03-20 2021-09-23 Institut De Cardiologie De Montreal Methods of treating a coronavirus infection using colchicine
KR20220158821A (ko) * 2020-03-27 2022-12-01 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
TW202210068A (zh) * 2020-06-05 2022-03-16 美商雅力思提雅治療公司 用於治療家族性地中海型發熱病的cxcr-2抑制劑

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
EP2241328A1 (en) * 2000-05-12 2010-10-20 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
CN104178491B (zh) 2002-09-06 2018-07-03 安姆根有限公司 治疗性人抗-il-1r1单克隆抗体
US20050129685A1 (en) * 2003-09-18 2005-06-16 Jingtai Cao Use of IL-1 blockers to prevent corneal inflammation and neovascularization

Similar Documents

Publication Publication Date Title
Kopf et al. Averting inflammation by targeting the cytokine environment
CA2568352A1 (en) Methods of using il-1 antagonists to treat autoinflammatory disease
Malcova et al. IL-1 inhibitors in the treatment of monogenic periodic fever syndromes: from the past to the future perspectives
Nishimoto Interleukin‐6 as a therapeutic target in candidate inflammatory diseases
ES2660036T3 (es) Moléculas de anticuerpo humanizadas específicas para IL-31
Izuhara et al. IL-4 and IL-13: their pathological roles in allergic diseases and their potential in developing new therapies
JP2009539349A5 (enExample)
Geyer et al. Actual status of antiinterleukin-1 therapies in rheumatic diseases
JP2011507891A5 (enExample)
JP2017079785A5 (enExample)
Tanasescu et al. Advances in the treatment of relapsing-remitting multiple sclerosis
HRP20150790T1 (hr) Režimi imunoterapije koji ovise o statusu apoe
JP2009510025A5 (enExample)
JP2012517818A5 (enExample)
JP2006506465A5 (enExample)
RU2018100129A (ru) Способы лечения подагры
NZ597915A (en) Combination therapy for treatment of immune disorders
US10456456B2 (en) Anti-IL-6 vaccine composition
SK12082002A3 (sk) Použitie IL-18 inhibítorov a farmaceutický prostriedok s obsahom IL-18 inhibítorov
Nishimoto Clinical studies in patients with Castleman’s disease, Crohn’s disease, and rheumatoid arthritis in Japan
McDermott Rilonacept in the treatment of chronic inflammatory disorders
Finckh et al. At the horizon of innovative therapy in rheumatology: new biologic agents
Çakan et al. Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases
Scharl et al. new anti-cytokines for IBD: what is in the pipeline?
JP2006508039A5 (enExample)